Aditxt (NASDAQ:ADTX – Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.
Analyst Recommendations
This is a summary of current ratings for Aditxt and Lyra Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
| Lyra Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Aditxt and Lyra Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
| Lyra Therapeutics | N/A | N/A | N/A |
Volatility and Risk
Aditxt has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500.
Earnings and Valuation
This table compares Aditxt and Lyra Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aditxt | $14,336.00 | 0.02 | -$41.71 million | ($100,788.35) | -0.00 |
| Lyra Therapeutics | $600,000.00 | 0.09 | -$28.92 million | ($19.15) | -0.00 |
Lyra Therapeutics has higher revenue and earnings than Aditxt. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
15.5% of Aditxt shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Lyra Therapeutics beats Aditxt on 9 of the 11 factors compared between the two stocks.
About Aditxt
Aditxt, Inc. is a biotechnology company focused on developing technologies for immune-system monitoring and modulation. Its AditxtScore platform is designed to measure and profile immune responses, with potential applications in tracking immune health and supporting personalized care. The company has also pursued immune-reprogramming approaches intended to promote immune tolerance in areas such as autoimmune disease, allergies and transplant rejection. Through its operating businesses and strategic initiatives, Aditxt has expanded its activities into diagnostics and other health-related technologies.
About Lyra Therapeutics
Lyra Therapeutics is a U.S.-based biotechnology company that has focused on developing localized treatments for chronic rhinosinusitis, a long-lasting inflammatory condition affecting the nose and sinuses. The company’s investigational candidates, LYR-210 and LYR-220, are bioabsorbable implants designed to deliver mometasone furoate, a corticosteroid, directly to nasal and sinus tissues over an extended period. The treatments were developed for administration by a health care provider, with the goal of providing sustained therapy without relying solely on daily medication.
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.
